Hepatic arterial infusion of the nitrosourea derivate fotemustine for the treatment of liver metastases from colorectal carcinoma

1997 ◽  
Author(s):  
J Hartmann ◽  
E Schmoll ◽  
C Bokemeyer ◽  
R Fety ◽  
C Lucas ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Liver Metastases ◽  
Hepatic Arterial Infusion ◽  
Arterial Infusion

Hepatic Arterial Infusion (HAI) for Unresectable Liver Metastases (ULM) from Colorectal Carcinoma

1997 ◽  
Vol 83 (1_suppl1) ◽  
pp. 61-61 ◽  
Author(s):  
Donato Nitti ◽  
Pierpaolo Da Pian ◽  
Pierluigi Pilati ◽  
Stefano Bacchetti ◽  
Guido Meneghetti ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Liver Metastases ◽  
Hepatic Arterial Infusion ◽  
Arterial Infusion ◽  
Unresectable Liver Metastases

Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial.

1992 ◽  
Vol 10 (7) ◽  
pp. 1112-1118 ◽  
Author(s):  
P Rougier ◽  
A Laplanche ◽  
M Huguier ◽  
J M Hay ◽  
J M Ollivier ◽  
...  
Keyword(s):  
Survival Rate ◽  
Colorectal Carcinoma ◽  
Liver Metastases ◽  
Randomized Study ◽  
Hepatic Metastases ◽  
Hepatic Arterial Infusion ◽  
Long Term Results ◽  
Control Group ◽  
Arterial Infusion ◽  
Extrahepatic Metastases

PURPOSE A multicentric randomized study that compared patients who received intrahepatic arterial infusion (HAI) to a group of patients who did not receive HAI (control group) was performed for unresectable hepatic metastases from primary colorectal carcinoma. PATIENTS AND METHODS One hundred sixty-six patients were assigned randomly to HAI of floxuridine (5 fluoro-2'deoxyuridine [FUDR]) 0.3 mg/kg/d for 14 days every 4 weeks or to the control group; this latter group, depending on the investigator's choice, was either under observation or received systemic fluorouracil (5-FU). The same regimen of systemic 5-FU also was administered to the HAI group in the event of extrahepatic progression. No crossover from the control group to the HAI group was permitted. The mean duration of follow-up was 54 months (range, 31 to 72), and 163 patients were analyzed. RESULTS A significant improvement was observed in the survival rate for the 81 patients assigned to HAI group (P less than .02) with a 1-year survival rate of 64% versus 44% in the control group (82 patients). The 2-year survival rate was 23% versus 13%. The median survival was 15 months versus 11 months for the HAI group and the control group, respectively. Survival was better for patients with a less than 30% liver involvement, and for those treated in more specialized centers. The hepatotoxic effects of HAI were observed in 47 patients (chemical hepatitis [n = 28], and biliary sclerosis [n = 19]). The 1-year rate of sclerosing cholangitis was equal to 25%. Gastrointestinal toxicity was infrequent and consisted of gastritis or diarrhea. CONCLUSIONS Therapy with HAI of FUDR improves the survival of patients with liver metastases over colorectal carcinoma. However, the methods that are used to diminish the toxicity of HAI and efficient systemic chemotherapy, such as a combination of 5-FU and leucovorin, are required to prevent extrahepatic metastases.

Randomized, Multicenter Trial of Fluorouracil Plus Leucovorin Administered Either Via Hepatic Arterial or Intravenous Infusion Versus Fluorodeoxyuridine Administered Via Hepatic Arterial Infusion in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma

2000 ◽  
Vol 18 (2) ◽  
pp. 243-243 ◽  
Author(s):  
Matthias Lorenz ◽  
Hans-Helge Müller ◽  
Keyword(s):  
Colorectal Carcinoma ◽  
Liver Metastases ◽  
Randomized Study ◽  
Skin Irritation ◽  
Liver Volume ◽  
Elevated Serum ◽  
Hepatic Arterial Infusion ◽  
Fold Increase ◽  
Survival Times ◽  
Arterial Infusion

PURPOSE: To assess the efficacy and tolerability of three treatments for patients with documented adenocarcinoma of the colon and/or rectum who have undergone complete resection of primary tumor and have nonresectable liver metastases that do not exceed 75% of the liver volume. PATIENTS AND METHODS: A total of 168 patients at 25 treatment centers were enrolled onto this prospective, multicenter, randomized study. The three treatment arms were as follows: (1) fluorouracil (5-FU)/leucovorin (LV) administered via hepatic arterial infusion (HAI), (2) 5-FU/LV administered via intravenous (IV) infusion, and (3) fluorodeoxyuridine (FUDR) administered via HAI. RESULTS: Median times to disease progression for the three treatment arms were as follows: 9.2 months for patients treated with HAI 5-FU/LV, 6.6 months for IV 5-FU/LV, and 5.9 months for HAI FUDR. Median survival times for patients treated with HAI 5-FU/LV, IV 5-FU/LV, and HAI FUDR were 18.7 months, 17.6 months, and 12.7 months, respectively. There was a nearly two-fold increase in time to progression in addition to a survival benefit among patients with an intrahepatic tumor burden of less than 25% who were treated with HAI 5-FU/LV. The most common adverse events were stomatitis, nausea and vomiting, skin irritation, diarrhea, and elevated serum levels of liver enzymes. Some patients exhibited severe reactions, including biliary sclerosis and chemical hepatitis. CONCLUSION: Although the use of HAI 5-FU/LV as a means of treating liver metastases after resection of colorectal carcinoma warrants further investigation, it cannot be recommended as a routine therapeutic measure at this time.

Sign in / Sign up

Export Citation Format

Share Document